Literature DB >> 9952058

Polymorphisms of the dopamine D4 receptor and response to antipsychotic drugs.

B M Cohen1, D J Ennulat, F Centorrino, S Matthysse, H Konieczna, H M Chu, S Cherkerzian.   

Abstract

The dopamine D4 receptor may be a site through which the clinical effects of antipsychotic drugs are mediated. Polymorphisms of a 48 base pair repeat in the third exon of the DRD4 gene code for different length segments in the third intracytoplasmic loop of the D4 receptor. The most common long (seven repeat) form of the D4 receptor has been shown in both physiologic and pharmacologic experiments to respond differently to dopamine agonists and antagonists than do shorter forms of D4. Thus, variants of D4 may partly determine patient response to antipsychotic drugs and, in particular, response to typical neuroleptics, which have a relatively low affinity for the D4 receptor, as compared to clozapine, which has a relatively high affinity for D4. DRD4 polymorphisms in the third intron were characterized in 28 patients with chronic psychosis who responded well to typical neuroleptics, 32 patients who responded well to clozapine, and 57 healthy comparison subjects. Patients responding to typical neuroleptics carried the allele for the long (seven repeat) form of the D4 receptor (allele frequency 8.9%) less frequently than patients responding to clozapine (allele frequency 23.4%, P = 0.046) or healthy comparison subjects (allele frequency 26.3%, P = 0.004). The results of this study suggest that inherited variants of D4 may explain some of the interindividual variation seen in patient response to different classes of antipsychotic medication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9952058     DOI: 10.1007/s002130050799

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Receptor pharmacogenetics: relevance to CNS syndromes.

Authors:  Sanober Shaikh; Robert W Kerwin
Journal:  Br J Clin Pharmacol       Date:  2002-10       Impact factor: 4.335

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

Review 3.  Pharmacogenetics in health-care practice.

Authors:  der Zee Anke-Hilse Maitland-van; Olaf H Klungel; Anthonius de Boer
Journal:  Pharm World Sci       Date:  2004-10

4.  Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Authors:  Peter Heusler; Liesbeth Bruins Slot; Isabelle Rauly-Lestienne; Christiane Palmier; Stéphanie Tardif; Amélie Tourette; Marie-Christine Ailhaud; Didier Cussac
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-06       Impact factor: 3.000

Review 5.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 6.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 7.  Pharmacogenetics of response to antipsychotics in patients with schizophrenia.

Authors:  Maria J Arranz; Margarita Rivera; Janet C Munro
Journal:  CNS Drugs       Date:  2011-11-01       Impact factor: 5.749

Review 8.  Pharmacogenetics as a tool in the therapy of schizophrenia.

Authors:  Bob Wilffert; Rianne Zaal; Jacobus R B J Brouwers
Journal:  Pharm World Sci       Date:  2005-02

Review 9.  Pharmacogenomics: marshalling the human genome to individualise drug therapy.

Authors:  W E Evans
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

10.  Toward a modern search for schizophrenia genes.

Authors:  M Leboyer
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.